Approval for the VENTANA ALK (D5F3) CDx Assay.  The device is intended for the qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) tissue stained with a BenchMark XT or BenchMark ULTRA automated staining instrument. It is indicated as an aid in identifying patients eligible for treatment with XALKORI (crizotinib) or ZYKADIA (ceritinib) or ALECENSA (alectinib).